Vividion Therapeutics, Inc.

23 articles with Vividion Therapeutics, Inc.

• Vividion Therapeutics Appoints Christine Siu to Board of Directors

  5/4/2021

  Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Christine Siu, a life sciences industry leader with more than 20 years of experience in corporate development, strategy and financial roles, has joined the company’s board of directors.

• Vividion Therapeutics Expands Leadership Team with Key Regulatory and CMC Appointments

  4/20/2021

  Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, announced that Xiaohu Deng, Ph.D., has been appointed as head of technical operations and Lisa Percival has been appointed as head of regulatory.

• Vividion Names Patty Allen as Full-Time Chief Financial Officer and Welcomes Brian Koh, M.D., as Head of Translational Sciences and Clinical Development

  3/30/2021

  Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Patricia “Patty” Allen, who has served as acting chief financial officer of Vividion since January 2021, has joined the company as full-time CFO and that Brian Koh, M.D., has been appointed as head of translational sciences

• Vividion Appoints Catherine Friedman to Board of Directors

  3/24/2021

  Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced that Catherine Friedman, a financial industry expert with nearly 40 years of financial industry experience, has been appointed to the company’s board of directors.

• Vividion Announces $135 Million Series C Financing to Fuel Broad Pipeline of Precision Oncology and Immunology Programs

  2/24/2021

  Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, today announced the completion of a $135 million Series C financing, co-led by new investors, Logos Capital and Boxer Capital of Tavistock Group.

• Vividion Brings in Proven Industry Leader Jeffrey Hatfield as Chief Executive Officer

  11/23/2020

  Vividion Therapeutics, a biotechnology company discovering and developing selective small molecule medicines that drug traditionally inaccessible targets, today announced that Jeffrey Hatfield has been appointed as the company’s chief executive officer.

• Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases

  5/19/2020

  Multi-Target Collaboration Leverages Vividion's Screening Platform to Discover and Develop Highly Selective Small Molecules for E3 Ligases and Select Oncology and Immunology Targets

• 

  Vividion and Roche Partner on Research Pact Worth "Several Billion Dollars"

  5/19/2020

  The companies will leverage Vividion’s proteomics screening platform and small molecule library to target novel E3 ligases in addition to a variety of oncology and immunology therapy targets.

• Vividion Therapeutics to Present Data on Novel Covalent E3 Ligase Engager Supporting Broad Targeted Protein Degradation at 2020 AACR Annual Meeting

  5/15/2020

  First Reported E3 Ligase Beyond Cereblon and VHL Shown to Support Broad Targeted Protein Degradation of Multiple Targets In Vivo   [15-May-2020]   SAN DIEGO , May 15, 2020 /PRNewswire/ -- Vividion Therapeutics, a biotechnology company discovering and developing highly selective small molecule medicines that drug traditionally inaccessible targets, today announced data des

• 

  Beyond COVID-19: Biotech Beach Companies Reinvigorate Small Molecules, Cannabinoids and More

  4/15/2020

  The COVID-19 battle dominates the news, but it doesn’t constitute all the news. Here’s what several Southern California Biotech Beach companies are doing that you might have missed.

• Vividion Therapeutics Appoints Drug Discovery and Development Expert, Robert Abraham, Ph.D., as Chief Scientific Officer

  2/11/2020

  Vividion Therapeutics, a biotechnology company discovering and developing highly selective small molecule medicines that drug traditionally inaccessible targets, today announced the appointment of Robert Abraham, Ph.D., as Chief Scientific Officer

• Vividion Therapeutics Announces Oversubscribed $82 Million Series B Financing

  4/30/2019

  Bolsters capital to advance lead programs into the clinic and broaden early-stage pipeline of therapeutics against previously intractable drug targets

• 

  Vividion Secures $82 Million to Advance Its Lead Programs into the Clinic

  4/30/2019

  For Vividion, the financing round comes about a year after the company forged a $101 million collaboration with Celgene.
• 

  Highlight: A Dozen of the Forbes 30 Under 30 in Healthcare

  11/14/2018

  Every year, Forbes creates a list of 30 Under 30, people under the age of 30 who have made a mark and show promise in various areas. They just came out with the 2019 30 Under 30: Healthcare. Here we highlight a dozen of the winners for their roles in biopharma-related endeavors.
• 

  Movers and Shakers Oct. 1

  10/1/2018

  Here's a look at who shook things up in the world of pharma and biotech this week.

• Vividion Therapeutics Expands Leadership Team with the Appointments of Fred Aslan, M.D., President and Chief Business Officer, and Larry Burgess, Ph.D., Head of Chemistry

  9/25/2018

  Vividion Therapeutics today announced the appointments of Fred Aslan, M.D. as President and Chief Business Officer and Larry Burgess, Ph.D. as Head of Chemistry.

• 

  Celgene Plans To File Second NDA for Ozanimod in 2019 Following FDA Rejection in February

  5/4/2018

  Celgene is eying the first quarter of 2019 to submit a second New Drug Application (NDA) for multiple sclerosis treatment ozanimod.
• 

  Celgene’s COO Resigns as Company Shakes up Leadership Structure

  4/3/2018

  Scott Smith, Celgene’s chief operating officer, abruptly resigned Monday. His decision to leave appears to be prompted by a restructuring of the company’s executive team.
• 

  Celgene Partners with Prothena Therapeutics in Potential $2B Deal

  3/21/2018

  Prothena Therapeutics has forged a collaboration with Celgene worth a potential $2B to develop new therapies for a broad range of neurodegenerative diseases.
• 

  Vividion Therapeutics Snags $101M from Celgene

  3/5/2018

  Celgene handed over $101 million in upfront monies to San Diego-based Vividion Therapeutics, Inc. as part of an agreement to develop small molecule therapies.